| Formulary Chapter 11: Eye - Full Chapter
|
| 11.04.01 |
Corticosteroids |
|
|
Betamethasone sodium phosphate 0.1% + Neomycin 0.5% drops
(Ophthalmic)
|
 Restricted
|
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes - NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- Restricted to Ophthalmology
|
|
|
Betamethasone sodium phosphate 0.1% drops/ointment
(Ophthalmic)
|
Formulary
|
Provider notes
- NMUH:
- RFL:
- Approved for inflammation in anterior segment, post-op to reduce inflammation
- RNOH:
- UCLH:
- WH:
|
|
|
Dexamethasone + Framycetin + Gramicidin drops
(Sofradex®)
(Ophthalmic)
|
Formulary
|
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes
|
|
|
Dexamethasone + Neomycin + Polymyxin B drops/ointment
(Maxitrol®)
(Ophthalmic)
|
Formulary
|
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
|
|
Dexamethasone 0.1% eye drops
(Ophthalmic)
|
Formulary
|
Provider notes
- NMUH:
- RFL:
- Inflammation in anterior segment, post-op to reduce inflammation
- RNOH:
- UCLH:
- WH:
|
|
|
Dexamethasone 0.1% eye drops - preservative free
(Ophthalmic)
|
Formulary
|
Provider notes
- NMUH:
- RFL:
- Inflammation in anterior segment, post-op to reduce inflammation (single-use drops & preservative-free bottles)
- RNOH:
- UCLH:
- WH:
- Dexamethasone eye drops 0.1% preservative-free (Moorfields)
|
|
|
Dexamethasone intravitreal implant
(Ozurdex®)
(Ophthalmic)
|
Restricted
 
|
See NICE TA for eligibility criteria
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- To be prescribed by Consultant Ophthalmologists ONLY for the treatment of Macular Oedema Secondary to Retinal Vein Occlusion as per NICE guidance.
- See links below
- RFL:
- Approved for macular oedema following RVO in line with NICE TA (Ophthalmologist use only)
- RNOH:
- UCLH:
- WH:
|
 NCL JFC: Branch Retinal Vein Occlusion (BRVO) Pathway
NCL JFC: Central Retinal Vein Occlusion (CRVO) Pathway
 NICE TA229: Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion
NICE TA349: Dexamethasone intravitreal implant for treating diabetic macular oedema
NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis
|
Fluocinolone acetonide intravitreal implant
(Iluvien®)
|
Restricted
|
See NICE TA for eligibility criteria
Provider notes
- NMUH:
- This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- To be prescribed by Consultant Ophthalmologists ONLY for the treatment of Macular Oedema Secondary to Retinal Vein Occlusion as per NICE guidance.
- See links below
- RFL:
- Approved for diabetic macular oedema in line with NICE TA (Ophthalmologist use only)
- RNOH:
- UCLH:
- WH:
- For Diabetic macular oedema after an inadequate response to prior therapy (Nov 2013 TA301)
|
NCL JFC: Diabetic Macular Oedema (DMO)
NICE TA301: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy
NICE TA590: Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis
NICE TA613: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy
|
Fluorometholone 0.1% eye drops
(FML®)
(Ophthalmic)
|
Formulary
|
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
|
|
Hydrocortisone sodium phosphate 3.35 mg/ml drops
(Softacort®)
(Ophthalmic)
|
Restricted
|
Approved for mild non-infectious allergic or inflammatory ocular surface diseases (JFC September 2019)
Provider notes
- NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
|
|
|
Loteprednol 0.5% eye drops
(Ophthalmic)
|
Restricted
|
Provider notes
- NMUH:
- RFL:
- Restricted to steroid-responder patients requiring topical steroids (2nd line)
- RNOH:
- UCLH:
- WH:
|
|
|
Prednisolone eye drops (various strengths)
(Ophthalmic)
|
Formulary
|
Provider notes
- NMUH:
- No restriction stated (0.5% and 1% available)
- RFL:
- No restriction stated (0.3% and 1% available)
- RNOH:
- No restriction stated (0.5% and 1% available)
- UCLH:
- WH:
- No restriction stated (0.5% and 1% available as licensed products; 0.3% and 0.03% available as unlicensed specials)
|
|
|
Prednisolone eye drops (various strengths) - preservative free
(Ophthalmic)
|
Formulary
|
Provider notes
- NMUH:
- No restriction stated (0.5%)
- RFL:
- No restriction stated (0.1% bottles, 0.3% bottles, 0.5% single-use)
- RNOH:
- UCLH:
- WH:
- No restriction stated (0.5% available as licensed products; 0.1%, 0.3%, 0.03% 10mL bottles available as unlicensed specials)
|
|
|
Rimexolone 1% eye drops
(Ophthalmic)
|
Restricted
|
Provider notes
- NMUH:
- RFL:
- Approved for hypertensive uveitis
- RNOH:
- UCLH:
- WH:
|
|
|
Triamcinolone acetonide 40mg/1mL injection
(Kenalog®)
(Ophthalmic)
|
 Unlicensed
|
Provider notes
- NMUH:
- Use of Triamcinolone (Kenalog®) injection intravitreally is unlicensed
- See link below
- RFL:
- Approved for
- Uveitic Macular oedema
- Diabetic macular oedema
- RNOH:
- UCLH:
- WH:
|
NCL JFC: Diabetic Macular Oedema (DMO)
|
| .... |
| Non Formulary Items |
Dexamethasone + Tobramycin eye drops
(Tobradex®)
(Ophthalmic)
|
Non Formulary
|
|
|
|
Prednisolone 0.5% + Neomycin 0.5%
(Predsol-N®)
|
Non Formulary
|
|
|
|
| |
Key |
|
Traffic Light Status Information
| Status |
Description |
|
Medicines that should be initiated by a specialist. Prescribing can be transferred to primary care once the patient has been stabilised.
Shared care: For drugs with regular, ongoing need for monitoring and/or assessment of efficacy or toxicity. Prior agreement must be obtained by the specialist from the primary care provider before prescribing responsibility is transferred. The shared care protocol must have been agreed by the relevant secondary care trust Drugs and Therapeutics Committee(s) (DTC) and approved by the North Central London JFC.
Fact sheet: For drugs with some concerns surrounding safety or efficacy but do not require regular monitoring and/or monitoring of effectiveness/toxicity. |
|
Medicines which should normally be prescribed by specialists only (hospital only).
For patients already receiving prescriptions in primary care - continue. No new patients to receive prescriptions in primary care.
See link for the complete NCL Red List https://www.ncl-mon.nhs.uk/wp-content/uploads/2017/08/ncl_red_list.pdf |
|
Medicines not recommended for routine use in primary or secondary care.
Medicines, which the North Central London JFC has actively reviewed and does not recommend for use at present due to limited clinical and/or cost effective data. |
|
|
|
